We help businesses add human faces to real-time AI chatbots, assistants and agents. Our customers typically build AI tutors, AI receptionists, AI coaches, AI mock interviews, AI employee onboarding, you get the picture! Try talking to a human avatar here: https://www.simli.com/demo Our Docs: https://docs.simli.com/introduction Discord: https://discord.com/invite/yQx49zNF4d

Let's achieve results together We create a successful service together that you can be proud of, and that makes you the job's digital expert. We have extensive experience and promise you a process where you can breathe a sigh of relief and avoid budget cracks, delayed deliveries, and sour emails to customer service. It requires you to set aside time to work with us. This is not free time in your calendar today. You have to prioritize collaboration, and that means downplaying something else. We promise that the time you set aside will yield great results. You can measure the difference before and after you have worked with us. More satisfied visitors? More, new members? More money at the checkout? We help you not only to reach your goals but to know that you have reached them. And you? It's going to be fun too. We thrive with each other here in Netlife, and we are very happy with everyone we work with. We are not just going to "deliver" something, we are really committed.

We are foodies that aim to change the chocolate and dessert space. A plant-based, sustainable, and socially responsible product series that most people like does not exist, and we want to change this with VGAN.Our goal is to make the world a slightly better place one bite at a time. VGAN is a small Norwegian company. We have developed å high-quality chocolate with acceptance in the market. VGAN– our lifestyle chocolate is to enjoy with a clear conscience It is better for the environment It is better for your health It is made sustainable The VGAN brand is already registered and protected for all snacking categories in the US and the EU The chocolate is organic, fair trade, gluten-free, soy-free, certified kosher, and of course none GMO.

Norwegian Block Exchange AS (NBX) was established in 2018 and is working with distributed ledger technologies. NBX’s offices are located at Fornebu in Bærum, Norway. NBX is building the next-generation cryptocurrency exchange to set a new standard for security, transparency, and reliability within cryptocurrency trading. We start from scratch and only use the best-in-class solutions and technology. The company will also work on the adaption of DLT to find better and smarter ways for businesses across industries to operate. NBX has global ambitions and to reach the goals we build the company by working with the best people and partners.

Hello! We are yne. The consulting company by developers, for developers! We build the consulting house of the future with cutting-edge expertise in front-end development, to create the technology you want to use. Easily. We started Yne with a burning desire to challenge the established consulting industry's way of thinking. Today, we are a forward-leaning and innovative company - by developers, for developers. Yne is a consultancy firm built by consultants. We want to be a small firm where your colleagues are your friends. We want to build a profitable company where the employees also have fun social events.

Society Lab is an EdTech company with international ambitions. We create the "digital gym" that gets leaders in shape to master tomorrow and fast-track an inclusive and sustainable economy. We use technology to tailor learning to the individual leader and we offer to learn as a subscription. Through this, we will help companies close the competence gap so that they become relevant also tomorrow. We have successfully passed the first phase of being a start-up, have customers, are financially solid, have come a long way in verifying our concept in the market, and will now rig to build the technology to scale the company.

You will find 128 million contact lens users worldwide in a 7.5 billion dollar industry and most of them have trouble inserting and/ or removing contact lenses. The result can be as mild as red and irritating eyes and the need to use glasses for a couple of days, but also worst case scenario having to surgically remove the eye. We have designed and created a patented product for inserting and removing contact lenses with a container for keeping the product clean and sterile so you can take it with you.

Cavai AS was founded in December 2017 with the goal of revolutionizing online advertising. User experiences have largely been neglected on the web, and Cavai saw early on that chatbot technology, which has initially been used in customer service, could be a wonderfully good advertising product. Usually, chatbot technology is used as customer service on its own website, while Cavai's platform is built to be able to use chatbot technology on millions of websites for contextual advertising. The team today consists of 15 people, and the product has been launched in Norway, Finland, Sweden and the UK with 50 paying customers. Customers are very pleased and report that Cavai's technology is having a very good effect on completed advertising campaigns. Cavai will have its first month of positive operating results in October and looks to have sales of around 3 million in 2019. Next year will be a big growth year, where we have budgeted with a turnover of NOK 41 million. This growth has also been discussed by Finansavisen, where as part of Finansavisen's web-TV series "Vext", Cavai filmed his meeting with advertising legend Sir Marting Sorell in London. For more information, see https://finansavisen.no/vext/tech/2019/10/23/7465643/chatbot-company-cavai-2020-blir-the-store-growst>  To finance further growth, we are now running a seed funding round of NOK 9.5 - 15 million. The company is priced at NOK 60 million pre-money. For more information see the investor summary, investor presentation and subscription form attached.

Vi ønsker å gi etterlatte sinnsro og vår visjon er at alle som ønsker det, skal få hjelp med å ivareta et gravsted. Memodo er etablert og basert i Oslo. Vi ønsker å tilby etterlatte en trygg plattform hvor de kan dele sine minner. En digital gravplass, knyttet opp mot den fysiske, som kan være et samlingspunkt for de etterlatte. Memodoteamet består av et nasjonalt nettverk av profesjonelle ivaretakere, som jobber for å levere en verdig tjeneste. Memodos verdier er: profesjonell, pålitelig, trygg og moderne.

SonoClear AS develops an acoustic contrast fluid to remove noise in ultrasound images, used during brain tumor surgery to guide tumor removal. The goal is to be sure that all tumor is removed, as total resection improves patient outcomes. The technology is developed by neurosurgeons at St.Olavs hospital and engineers at Sintef. The technology is patented worldwide and is developed as a medical device according to ISO13485. The core team consists of CTO, Medical advisor, Quality manager, and Regulatory officer. SonoClear plan for market access in USA and EU in 4q20 and 4q21, respectively.

SandTools AS: Hardware Innovation & Sales company.Work Ethics: Verified steps. Hope is not a strategy. We are developing an intelligent Construction & Landscaping tool for international sales. Functioning prototype 5 has been tested in Norway, Sweden, and Denmark. Freedom to Operate and IPR is secured (WIPO Industrial Design)Market research tells a good story, with a 75% score among relevant users in the EU. Relevant users were found through a joint effort with SSB and Eurostat. The market's demand ratio of 75% forecasts actual sales of 5-20%. Preordering has started—the first investor (Jetro AS) is in place regarding Electronic Product Development. We are looking for Investor/partner for production and sales kick-off.

Modern, nobel-prize winning research shows that hardly any traditional investment funds are adding any value beyond what fully automated strategies can do. NorQuant's mission is to help private and professional investors achieve higher returns at lower costs through a scientific, rules-based, 100% transparent approach. We feel we are off to a good start: - We are helping our first pilot customer, one of Norway's largest family offices, implement factor-based analysis - We have been selected as one of ten fintech-startups for TheFactory.no Fall18 program, out of more than 200 applications

Waste management solutions. Primary machines and equipment, but also consulting. We make a profit by helping customers reduce their costs (and even make a profit). Enterprises can save/make money by focusing on the environment.  Both parties win. Eco-Nor Group may consider investors to cooperate with good and long-term partners as a matter of urgency.

We have developed a system for calculating and supplying Solcelle, and wind power for Scandinavia. In addition to this, we have obtained a license as a power supplier, so we can offer our customers both purchases and sales of green power. Why solar cells? Sun provides energy. As an energy source, the sun is unsurpassed. Every year, the earth receives 15,000 times more energy from the sun than the earth's population uses. Even in Norway, the sun provides 1,500 times more energy than what we use. Depending on where on the globe you are, the sun provides an amount of energy from 700 to over 2,200 kWh/m2 per year.

Oncoinvent AS is a privately held Norwegian company established in 2010. The company is committed to developing new innovative products to provide better treatment options to cancer patients. The innovations being developed by Oncoinvent AS are a result of the extensive experience with the development of radionuclide-based cancer treatments of two of the founders, Dr. Roy H. Larsen and Professor of clinical oncology Øyvind S. Bruland. Larsen and Bruland are the inventors of the first FDA and EMA-approved alpha-emitting pharmaceutical product Xofigo® (Bayer AG), as well as of the beta-emitting radio-immunotherapeutic product candidate Betalutin® (Nordic Nanovector ASA). Oncoinvent's lead product candidate, Radspherin®, is a novel alpha-emitting radioactive microsphere designed for the treatment of metastatic cancers in body cavities. Radspherin® has been shown to cause a significant reduction in tumor cell growth. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin® will be the treatment of peritoneal carcinomatosis. Clinical development will be conducted in collaboration with European and American clinical research centers.